All PlansAdministrativeMedium impact
MA08.024o, Interleukin-5 (IL-5) Antagonist (e.g., Cinqair®, Exdensur, Nucala®) and IL-5 Receptor Antagonist (e.g., Fasenra®)
Independence Blue Cross·Pharmacy
We identified it
Jul 2, 2026
Summary
Failed to analyze policy change